Psilocybin has not been shown to restore movement after stroke in a completed human trial. A recruiting Johns Hopkins University Phase 1 study called PHATHOM is testing short-term safety in 20 adults with chronic stroke and collecting secondary motor data. If you are considering the study, treat it as early clinical research and continue the rehabilitation and stroke-prevention plan set with your medical team. 1
Psilocybin Stroke Recovery Clinical Trial at a Glance
You will find PHATHOM in the federal trial registry as NCT07053917. Its full name is Psychedelic Healing Adjunct Therapy Harnessing Opened Malleability. Johns Hopkins University is the sponsor and Baltimore, Maryland is the study location. The record listed the trial as recruiting when checked on August 4, 2026. 1
| Trial feature | Registered detail |
|---|---|
| Registry number | NCT07053917 |
| Phase | Phase 1 |
| Status | Recruiting when checked on August 4, 2026 |
| Planned enrollment | 20 adults |
| Stroke stage | At least 12 months after stroke |
| Stroke types | Ischemic or hemorrhagic stroke confirmed by CT or MRI |
| Study design | Randomized, parallel assignment and open label |
| First dose schedule | One 25 mg psilocybin dose |
| Second dose schedule | 12.5 mg followed by 12.5 mg two hours later |
| Primary outcome | Protocol-defined systolic and diastolic blood pressure stability through 24 hours |
| Selected secondary measures | Adverse events, vital signs, cardiac measures, psychiatric symptoms, seizure monitoring, the National Institutes of Health Stroke Scale and the Fugl-Meyer Upper Extremity Motor Assessment |
| Estimated primary completion | February 28, 2027 |
| Estimated study completion | March 31, 2027 |
The trial compares two schedules that deliver the same total 25 mg dose. If you enter one group, you receive 25 mg once. If you enter the second group, you receive 12.5 mg and another 12.5 mg two hours later. Your assignment is random. You and the investigators know which schedule you receive because the study is open label. 1
You will not enter a placebo group or a standard-rehabilitation control group. The design can compare the immediate safety of the two dosing schedules. It cannot show how psilocybin performs against rehabilitation alone.
What the PHATHOM Study Is Testing
If you participate, the primary outcome concerns four protocol-defined blood pressure stability rules during the first 24 hours. The rules address sustained systolic readings above 180 mm Hg or below 70 mm Hg and sustained diastolic readings above 120 mm Hg or below 40 mm Hg. Each rule requires more than two readings sustained for longer than 20 minutes. 1
These thresholds are research endpoint rules. Your usual blood pressure targets after stroke may differ based on your stroke type, medical history, medicines and clinician assessment.
Your motor function would be a secondary area of study. The registry lists the Fugl-Meyer Upper Extremity Motor Assessment, a 66-point assessment of arm motor impairment. It also lists the National Institutes of Health Stroke Scale, which measures neurologic impairment across several domains. 1
If your secondary motor score changes, the finding would count as an early signal. A larger controlled trial would still be needed to test clinical efficacy. That trial would need a defined rehabilitation program, prespecified functional outcomes and follow-up long enough to show how long any change lasts.
Why Psilocybin Is Being Studied After Stroke
Your brain can adapt after a stroke by changing activity within surviving cells and networks. Clinicians refer to this capacity as neuroplasticity. Rehabilitation uses repeated and task-specific practice to direct that activity toward useful movement, communication and daily function. Your response can vary with lesion location, tract damage, impairment severity, treatment dose, medical status and time since stroke. 10 11
Researchers are asking if psilocybin can temporarily change the brain state in which you receive rehabilitation. The proposed effect would depend on active training during that period. Current human evidence has not shown that this process improves movement after stroke.
You can see a credible scientific basis for controlled testing in studies of receptor activity and learning-related changes. Researchers can examine those measures during rehabilitation. The findings support clinical research under medical supervision. They do not support self-directed treatment. 7 4
What Human Stroke Rehabilitation Research Shows
You can see the effect of rehabilitation timing in the Critical Period After Stroke Study, which did not use psilocybin. Researchers randomized 72 participants to usual care alone or 20 extra hours of upper-limb therapy. The added treatment began within 30 days, between 60 and 90 days or at least six months after stroke. 3
The largest treatment effect appeared when therapy began between 60 and 90 days after stroke. The fixed 20-hour program did not produce a statistically significant benefit when it began at least six months after stroke. The result shows that timing can influence response to a defined rehabilitation program. It does not show that you cannot improve during chronic stroke recovery.
If you qualify for PHATHOM, your stroke occurred at least 12 months earlier. This timing allows researchers to study safety after the earlier phase of heightened recovery response has passed. A small open-label safety study cannot prove that psilocybin reopens a human motor-learning period.
Limits of the Animal and Mechanistic Evidence
Human Receptor Research
Psilocybin is converted in your body to psilocin. Psilocin interacts with several serotonin receptors, including the serotonin 2A receptor.
When you read the human receptor evidence, you will find a positron emission tomography study involving eight healthy volunteers. Plasma psilocin levels and cerebral serotonin 2A receptor occupancy were associated with the intensity of subjective drug effects. The study supports receptor engagement in humans. It provides no motor-recovery data from people with stroke. 7
Mouse Critical-Period Research
A 2023 study in Nature gives you the main source for the critical-period claim. Psilocybin reopened a critical period for social reward learning in adult mice. The effect was present at one and two weeks in that model and was no longer present at three weeks. 4
The experiment studied social learning in mice. It did not test physical therapy, damaged human motor pathways or functional recovery after stroke. You should not read the two-week finding as a proven rehabilitation window in people.
Rat Stroke Research
When you review the stroke-specific animal evidence, you will find a 2024 rat study that used middle cerebral artery occlusion to model acute ischemic stroke. Psilocybin given before the injury reduced measured infarct size and neurologic deficits. Dosing on days 3 through 7 after injury improved locomotor measures. 5
You should read the brain-derived neurotrophic factor finding at the same animal-evidence level. A BDNF receptor inhibitor reduced several measured effects, which identifies BDNF-related signaling as a candidate mechanism in that rat model.
The study used small animal groups and an acute stroke model. Its routes, timing and clinical setting differ from PHATHOM. The findings cannot establish benefit for you if your stroke occurred months or years earlier.
Scientific Commentary
You can use a 2025 article in Brain to read about plasticity, metaplasticity, network effects and inflammatory signaling as research hypotheses for psychedelic-assisted stroke rehabilitation. Metaplasticity refers to a change in your nervous system’s readiness to undergo later plastic changes. 6
You should treat the article as a scientific perspective. It adds no human stroke efficacy data and several proposed mechanisms rely on cell or animal research. Clinical trials must test which pathways occur after human stroke and if measured changes lead to better function.
How Rehabilitation Fits the Psilocybin Hypothesis
You will find psilocybin combined with physical therapy in digitally enriched settings in Johns Hopkins project materials. The federal registry lists psilocybin as the intervention and records motor outcomes as secondary measures. 2 1
You cannot assess the rehabilitation dose, timing, digital platform or treatment fidelity from the public sources. The full protocol would be needed before the study could be described as a controlled test of a combined drug and rehabilitation program.
Your nervous system changes in response to repeated activity. Your rehabilitation may include reaching, grasping, walking, balance training, communication practice and daily-living tasks. Clinicians select the tasks according to your deficits, safety needs and treatment plan. 10
Your rehabilitation supplies the repeated activity that directs learning in the proposed model. Psilocybin exposure alone does not reproduce this research approach. Useful recovery would need to appear in your movement, daily function and participation. A general biological measure cannot show that result by itself.
Psilocybin Safety After Stroke
If you have had a stroke, the strongest human psilocybin safety data apply only indirectly to you. Those data come from screened adults in psychiatric trials. Stroke-specific safety data remain limited.
When you consider the known acute effects, the strongest pooled source is a 2024 systematic review of six randomized, double-blind trials involving 528 adults treated for depression or anxiety. Headache, nausea, anxiety, dizziness and elevated blood pressure occurred more often with psilocybin than with comparison treatments. Most reported acute effects resolved within 24 to 48 hours. 8
You cannot apply those safety results directly to every stroke survivor. The trials enrolled selected participants under controlled conditions and provide limited information about rare events, long-term effects or use in people with major cardiovascular, neurologic or medical conditions.
Cardiovascular Effects
Temporary increases in blood pressure have been reported during psilocybin sessions. If you have had a stroke, vascular disease or cardiac disease, these effects require careful clinical assessment. PHATHOM places blood pressure stability at the center of its primary outcome and includes short-term physiologic monitoring. 1 8
You should not use findings from a 20-person trial to define cardiovascular risk across all stroke survivors or estimate uncommon events reliably.
Psychological, Neurologic and Mobility Considerations
Psilocybin can cause anxiety, confusion, perceptual changes, nausea, headache and dizziness. An altered state can create extra risk if you have impaired balance, weakness, cognitive changes or communication difficulty. A research site can provide screening, observation and physical support during the dosing period. 8
The PHATHOM registry also includes psychiatric screening, seizure monitoring and restrictions related to several neurologic and psychiatric conditions. Only the study team can interpret those rules for your medical history. 1
Medicine Restrictions
If you take an antidepressant, mood stabilizer, antipsychotic, sedative medicine or antiseizure drug, the registry may exclude or restrict your participation during a specified period. It also screens you for medical, psychiatric and substance-use factors. 1
You should not interpret every protocol exclusion as proof of a harmful interaction. Some exclusions may support data interpretation or reduce uncertain risk in an early trial.
Do not stop or taper a prescribed medicine to seek trial entry unless the study team and your prescribing clinician direct and supervise the change. Abrupt changes can cause withdrawal, seizures, mood symptoms or recurrence of the condition being treated.
Who May Qualify for the PHATHOM Trial
You may be considered for screening if you meet the core registry criteria. The full screening process contains more requirements and may change. 1
- You are at least 18 years old.
- You had an ischemic or hemorrhagic stroke confirmed by CT or MRI.
- Your stroke occurred at least 12 months before admission.
- You can provide informed consent and complete the required study tasks.
- You can follow restrictions involving medicines, food, beverages and nicotine.
- You can arrange transportation after dosing and agree not to drive.
- You meet the protocol’s pregnancy testing and pregnancy-prevention requirements when applicable.
This list cannot determine your eligibility. A qualified study clinician must review your full medical history, current medicines, examination findings and required test results.
What Researchers Will Measure
If you participate, the registered primary outcome concerns blood pressure stability through 24 hours after psilocybin administration. Researchers also record adverse events, vital signs, cardiac measures, psychiatric symptoms and seizure-related information. 1
Your motor assessment would be secondary. The Fugl-Meyer Upper Extremity Motor Assessment measures arm impairment through tasks involving movement, coordination and reflex activity. The National Institutes of Health Stroke Scale measures your neurologic impairment across several domains.
A change in your impairment score does not automatically show better daily function. Later efficacy trials would need measures of your activity and participation, a clear rehabilitation schedule, an adequate comparison group and longer follow-up.
What Research Has Not Answered
Current evidence has not answered several questions that directly affect you.
- No published PHATHOM safety or motor results were available when the registry was checked on August 4, 2026.
- No dose or schedule has been shown to improve human motor recovery after stroke.
- The best timing between psilocybin exposure and rehabilitation is unknown.
- The amount and type of rehabilitation needed during a proposed learning period are unknown.
- Researchers cannot identify responsive lesion locations, impairment profiles or recovery stages from current data.
- Human data have not established how long a motor or functional change would last.
- Uncommon cardiovascular, neurologic and psychiatric risks in stroke survivors remain undefined.
For you, these gaps mean that PHATHOM should be read as a small safety study that comes before a larger efficacy trial. It can supply early information in a screened chronic-stroke population. Its design cannot provide a final answer about recovery.
Established Stroke Care Still Applies
You should know that no psilocybin product is approved by the US Food and Drug Administration for stroke rehabilitation as of August 4, 2026. The agency issued final guidance for psychedelic drug clinical investigations in July 2026. The guidance addresses clinical drug development and does not authorize psilocybin as a stroke treatment. 9 14
You should continue the rehabilitation and prevention plan established with your clinical team. Physical therapy, occupational therapy and speech-language therapy are used according to your assessed needs. Your care may also address spasticity, pain, swallowing, cognition, communication and mood symptoms. 10 11
Prevention of another stroke depends on your stroke type and cause. Your plan may include blood pressure treatment, lipid management, diabetes care, smoking cessation, physical activity and antiplatelet or anticoagulant treatment when indicated. 12
Treatment choices depend on your medical history, current medicines, age, pregnancy status, stroke type, stroke severity, disability and clinician assessment. Psilocybin should not replace established rehabilitation or secondary prevention.
When New Stroke Symptoms Require Emergency Care
If you develop sudden face, arm or leg weakness or numbness, speech difficulty, vision change, loss of balance or a severe unexplained headache, you may be having a new stroke. Call 911 immediately, even if your symptoms improve. Psilocybin research has no role in acute stroke treatment. 13
Frequently Asked Questions
Is There a Psilocybin Clinical Trial for Stroke Recovery?
Yes. PHATHOM, NCT07053917, is a recruiting Johns Hopkins University Phase 1 study in adults with chronic stroke. Its primary purpose is to assess short-term safety and tolerability. Researchers are also collecting neurologic and motor data. 1
Can Psilocybin Help You Recover Movement After a Stroke?
Published human evidence has not established that psilocybin improves movement after stroke. Animal studies and learning-related research support further clinical testing. You should treat claims of proven motor recovery as unsupported.
Why Does PHATHOM Enroll People at Least 12 Months After Stroke?
The study focuses on chronic stroke after the earlier phase of heightened recovery response. This criterion also creates a more consistent study population based on time since stroke. 1 3
Can You Take Psilocybin With Stroke Medicines?
No general answer applies to every patient. PHATHOM restricts many medicines and uses individual screening. Discuss every prescription medicine, nonprescription drug and supplement with the study team and your prescribing clinician. 1
Can You Reproduce the Study With Self-Directed Psilocybin Use?
Self-directed use lacks the study’s medical screening, product controls, physiologic monitoring, mobility support and follow-up. It cannot reproduce the PHATHOM protocol. Unsupervised use may expose you to cardiovascular, psychological, mobility and medication-related risks.
Are Psychedelics Approved for Stroke Rehabilitation?
No psychedelic drug is approved by the US Food and Drug Administration for stroke rehabilitation. Use in this setting remains investigational and should occur only under an authorized research protocol.
Following Psilocybin and Stroke Research
As you follow this research, we at Rose Hill Life Sciences work as a psychedelic research organization focused on the production and research of Psilocybe cubensis. Our work connects science with therapeutic integration, including our Massachusetts research work.
References
- ClinicalTrials.gov. Psychedelic Healing. Adjunct Therapy Harnessing Opened Malleability. NCT07053917. US National Library of Medicine. Record checked August 4, 2026.
- Johns Hopkins University. PHATHOM Stroke Project. 2026. Accessed August 4, 2026.
- Dromerick AW, Geed S, Barth J, et al. Critical Period After Stroke Study. A phase II clinical trial testing an optimal time for motor recovery after stroke in humans. Proceedings of the National Academy of Sciences. 2021.
- Nardou R, Sawyer E, Song YJ, et al. Psychedelics reopen the social reward learning critical period. Nature. 2023.
- Yu SJ, Wu KJ, Wang YS, et al. Neuroprotective effects of psilocybin in a rat model of stroke. BMC Neuroscience. 2024.
- Yang Y, Wang Y and Wang X. Harnessing psychedelics for stroke recovery. Brain. 2025.
- Madsen MK, Fisher PM, Burmester D, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019.
- Yerubandi A, Thomas JE, Bhuiya NMMA, et al. Acute adverse effects of therapeutic doses of psilocybin. JAMA Network Open. 2024.
- US Food and Drug Administration. Psychedelic Drugs. Considerations for Clinical Investigations. Final guidance. 2026. Accessed August 4, 2026.
- Winstein CJ, Stein J, Arena R, et al. Guidelines for Adult Stroke Rehabilitation and Recovery. Stroke. 2016.
- Stein J, Bierner SM, Dentel S, et al. American Heart Association Standards for Postacute Stroke Rehabilitation Care. Stroke. 2025.
- Kleindorfer DO, Towfighi A, Chaturvedi S, et al. Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke. 2021.
- Centers for Disease Control and Prevention. Signs and Symptoms of Stroke. 2026. Accessed August 4, 2026.
- US Drug Enforcement Administration. Psilocybin Drug Fact Sheet. Accessed August 4, 2026.
Disclaimer: The information in this article is for educational and informational purposes only and does not constitute medical advice.
